SWX:IDIA
SWX:IDIABiotechs

Assessing Idorsia (SWX:IDIA) Valuation After Recent Share Price Swings And Ongoing Losses

Idorsia (SWX:IDIA) has been drawing attention after a mixed set of recent returns. The stock is down about 17% over the past month but up roughly 10% over the past 3 months. See our latest analysis for Idorsia. At a share price of CHF3.645, Idorsia is coming off a 1 day share price return of about a 1% decline and a 30 day share price return of roughly a 17% decline. Its 1 year total shareholder return is very large, while the 3 and 5 year total shareholder returns remain deeply negative...
SWX:ALSN
SWX:ALSNElectronic

European Stocks That May Be Undervalued In January 2026

As the European markets navigate renewed trade and geopolitical uncertainties, with major indices like France's CAC 40 and Germany's DAX experiencing declines, investors are increasingly focused on identifying opportunities within this challenging environment. Amidst these fluctuations, finding undervalued stocks can be a strategic approach to potentially benefit from market inefficiencies and capitalize on businesses that may not fully reflect their intrinsic value due to current market...
SWX:YPSN
SWX:YPSNMedical Equipment

Is Ypsomed (SWX:YPSN) Quietly Redefining Its Drug-Delivery Edge With BD’s Large-Volume Collaboration?

In January 2026, BD (Becton, Dickinson and Company) and Ypsomed Holding AG expanded their partnership to develop a 5.5 mL BD Neopak XtraFlow Glass Prefillable Syringe fully compatible with Ypsomed’s YpsoMate 5.5 autoinjector platform, targeting large-volume subcutaneous biologic injections. This move highlights how device and syringe co-development can help pharmaceutical companies address rising drug volumes and viscosities while aiming to shorten combination-product development...
SWX:HIAG
SWX:HIAGReal Estate

How Investors May Respond To HIAG Immobilien Holding (SWX:HIAG) Profit Upgrade and CHF 100m Green Bond

In January 2026, HIAG Immobilien Holding AG announced that it expects consolidated net profit for 2025 to be 50% to 55% higher than the 2024 figure of CHF 75.2 million, meaning earnings should clearly exceed both last year’s result and prior market expectations. A few days earlier, the company had successfully placed a CHF 100 million green bond with a seven-year term and a 1.34% coupon, extending its average financing maturity while earmarking proceeds for sustainable buildings and projects...
SWX:COTN
SWX:COTNElectronic

High Growth Tech Stocks To Watch In Europe January 2026

As European markets navigate renewed trade and geopolitical uncertainty, with the pan-European STOXX Europe 600 Index ending 0.98% lower, investors are keenly observing high-growth tech stocks that could potentially thrive in this environment. In such a climate, a good stock is often characterized by its ability to adapt to changing market conditions and leverage technological advancements to maintain robust growth trajectories amidst broader economic challenges.
SWX:UBSG
SWX:UBSGCapital Markets

UBS Wealth Focus Highlighted By Forbes Honors And New Swiss Appointment

UBS Group (SWX:UBSG) saw four of its Southeast U.S. financial advisor teams ranked #1 in their respective cities by Forbes. The recognition focuses on UBS wealth management teams that serve high net worth and ultra high net worth clients. UBS also appointed Nicholas Hinnen as head of premium advisory specialists APAC Switzerland. Both developments relate to the firm’s focus on wealth management and premium advisory services. For you as an investor, these updates relate to the core of UBS...
SWX:LOGN
SWX:LOGNTech

Logitech International (SWX:LOGN) Q3 EPS Jump Reinforces Bullish Profitability Narratives

Logitech International (SWX:LOGN) has put up a solid Q3 2026 scorecard, with revenue of about US$1.4b and basic EPS of US$1.71 anchoring its latest quarterly update. The company has seen quarterly revenue move from US$1.01b in Q4 2025 to US$1.42b in Q3 2026, while basic EPS has ranged from roughly US$0.97 to US$1.71 over the same stretch. This gives you a clear sense of how the top and bottom line have tracked together. With trailing 12 month net profit margin sitting near the mid teens and...
SWX:IMPN
SWX:IMPNConstruction

Assessing Implenia (SWX:IMPN) Valuation After €350 Million In New Bridge And Tunnel Contracts

What the new contracts mean for Implenia stock Implenia (SWX:IMPN) has secured around €350 million of new bridge and tunnel projects in Germany and Norway, all tied to motorway links, mobility infrastructure and energy supply related transport corridors. For you as an investor, these contracts extend Implenia’s visibility on large, complex work across several years. Projects such as the Peene bridge, the Markbreit bridge replacement and the Riederwald tunnel form a sizeable order...
SWX:NESN
SWX:NESNFood

Nestlé Baby Formula Recall Raises Questions On Safety And Investor Risk

Nestlé (SWX:NESN) has recalled specific batches of baby formula after reports of contamination with the toxin cereulide. French authorities are investigating two infant deaths that may be linked to the recalled formula. National regulators have issued consumer warnings while inquiries into product safety and quality controls continue. Nestlé, listed as SWX:NESN, is a major global food and beverage group with a large presence in infant nutrition. When a core product such as baby formula is...
SWX:BANB
SWX:BANBLife Sciences

Why Bachem Holding (SWX:BANB) Is Up 9.6% After New NCE Deals And Cash Flow Gains

In recent trading, Bachem Holding drew strong attention after reports of new commercial NCE contracts, improved operating cash flow and better capacity utilization highlighted progress in its operations. These developments are being interpreted as potentially supporting a richer valuation multiple, even as some models flag risks and emphasize upcoming earnings and contract updates as key signposts. Next, we will examine how Bachem’s improved operating cash flow shapes its broader investment...
SWX:NOVN
SWX:NOVNPharmaceuticals

A Look At Novartis (SWX:NOVN) Valuation After Cardiovascular Breakthroughs And Digital Health Partnership News

Novartis (SWX:NOVN) has moved into focus after a series of high profile developments, including a World Economic Forum cardiovascular partnership, fresh drug pipeline updates, and recent share price strength ahead of upcoming earnings. See our latest analysis for Novartis. Those developments have arrived as the share price trades near its year high at CHF116.52, with a 30 day share price return of 5.83% and a 1 year total shareholder return of 30.56%, which hints at firm momentum rather than...
SWX:ARYN
SWX:ARYNFood

A Look At ARYZTA (SWX:ARYN) Valuation After New 2026 Revenue And Performance Guidance

Why ARYZTA’s 2026 outlook is in focus ARYZTA (SWX:ARYN) updated investors during its 2025 sales and trading statement call on 22 January 2026, pairing the update with fresh 2026 guidance that indicates revenue growth and improved performance. See our latest analysis for ARYZTA. ARYZTA’s latest 2026 guidance appears to have acted as a fresh catalyst, with a 7-day share price return of 9.4% and a 1-month share price return of 6.0%. This comes even though the 1-year total shareholder return is a...
SWX:SIKA
SWX:SIKAChemicals

Assessing Sika (SWX:SIKA) Valuation After Cain & Bultman Distribution Expansion

Cain & Bultman partnership puts Sika (SWX:SIKA) distribution in focus Sika (SWX:SIKA) is in the spotlight after Cain & Bultman agreed to distribute its floor covering installation products through commercial and residential dealers across several southeastern U.S. states, widening the company’s reach in that region. See our latest analysis for Sika. Sika’s CHF147.45 share price sits against a year to date share price return of 9.93% and a 1 year total shareholder return of 35.59% decline,...
SWX:GALE
SWX:GALEHealthcare

A Look At Galenica (SWX:GALE) Valuation After 2025 Sales Growth And Earnings Guidance Update

Galenica (SWX:GALE) has drawn fresh attention after reporting 2025 group sales of CHF 4,135.6 million, reaffirming dividend guidance, and confirming EBIT is expected to rise 10 to 12% following the Labor Team acquisition. See our latest analysis for Galenica. Those full year sales and earnings updates have arrived alongside a CHF97.25 share price, with a 15.16% 90 day share price return and a 23.46% 1 year total shareholder return suggesting momentum has strengthened recently. If you are...
SWX:IFCN
SWX:IFCNElectronic

INFICON Holding (SWX:IFCN) Valuation Check After 2025 Guidance Signals Flat Sales And Softer Margins

INFICON Holding (SWX:IFCN) issued preliminary 2025 guidance that points to sales of about US$673.7 million and operating income of roughly US$112.3 million, indicating stable revenue but softer profitability expectations. See our latest analysis for INFICON Holding. The share price reaction to INFICON Holding's guidance has come on top of strong recent momentum, with a 31.84% 1 month share price return and a 38.92% 3 month share price return. The 1 year total shareholder return of 14.85% and...
SWX:VACN
SWX:VACNMachinery

How VAT Group’s Q4 Order Rebound Amid Softer Sales At VAT Group (SWX:VACN) Has Changed Its Investment Story

In January 2026, VAT Group AG reported preliminary results showing fourth-quarter 2025 net sales of CHF 257 million, down from CHF 283.2 million a year earlier, while full-year 2025 net sales rose to CHF 1,073 million from CHF 942.2 million. An interesting detail is that preliminary fourth-quarter orders climbed to about CHF 305 million, growing both sequentially and year on year, even though full-year 2025 orders stayed roughly flat at around CHF 1,033 million. We will now examine how the...